Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer (SHIP0804)
A Phase III, Multicenter, Randomized, Controlled Study of Neoadjuvant LHRH-agonist Therapy and Permanent I-125 Implantation With vs. Without Adjuvant LHRH-agonist Therapy in Patients With Untreated Intermediate-risk Prostate Cancer.
Sponsor: The Jikei University School of Medicine
A PHASE3 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by The Jikei University School of Medicine and has accumulated 11 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — May 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Jikei University School of Medicine
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
For direct contact, visit the study record on ClinicalTrials.gov .